Adimmune Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was TWD 1,225.6 million compared to TWD 1,667.02 million a year ago. Net loss was TWD 226.02 million compared to net income of TWD 230.21 million a year ago. Basic loss per share from continuing operations was TWD 0.54 compared to basic earnings per share from continuing operations of TWD 0.54 a year ago. Diluted loss per share from continuing operations was TWD 0.54 compared to diluted earnings per share from continuing operations of TWD 0.54 a year ago.